140 related articles for article (PubMed ID: 21938754)
1. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm.
Chmielecki J; Peifer M; Viale A; Hutchinson K; Giltnane J; Socci ND; Hollis CJ; Dean RS; Yenamandra A; Jagasia M; Kim AS; Davé UP; Thomas RK; Pao W
Genes Chromosomes Cancer; 2012 Jan; 51(1):54-65. PubMed ID: 21938754
[TBL] [Abstract][Full Text] [Related]
2. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia.
Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC
Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533
[TBL] [Abstract][Full Text] [Related]
3. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.
Telford N; Alexander S; McGinn OJ; Williams M; Wood KM; Bloor A; Saha V
Blood Cancer J; 2016 Apr; 6(4):e412. PubMed ID: 27058227
[No Abstract] [Full Text] [Related]
5. A
Venable ER; Gagnon MF; Pitel BA; Palmer JM; Peterson JF; Baughn LB; Hoppman NL; Greipp PT; Ketterling RP; Patnaik MS; Kelemen K; Xu X
Cold Spring Harb Mol Case Stud; 2023 Feb; 9(1):. PubMed ID: 36627146
[TBL] [Abstract][Full Text] [Related]
6. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia.
Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S
Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986
[TBL] [Abstract][Full Text] [Related]
8. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate.
Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR
Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810
[TBL] [Abstract][Full Text] [Related]
9. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of the NUP98-CCDC28A fusion protein.
Petit A; Ragu C; Soler G; Ottolenghi C; Schluth C; Radford-Weiss I; Schneider-Maunoury S; Callebaut I; Dastugue N; Drabkin HA; Bernard OA; Romana S; Penard-Lacronique V
Haematologica; 2012 Mar; 97(3):379-87. PubMed ID: 22058212
[TBL] [Abstract][Full Text] [Related]
11. NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.
Byrgazov K; Kastner R; Gorna M; Hoermann G; Koenig M; Lucini CB; Ulreich R; Benesch M; Strenger V; Lackner H; Schwinger W; Sovinz P; Haas OA; van den Heuvel-Eibrink M; Niemeyer CM; Hantschel O; Valent P; Superti-Furga G; Urban C; Dworzak MN; Lion T
Leukemia; 2017 Jan; 31(1):237-240. PubMed ID: 27573554
[No Abstract] [Full Text] [Related]
12. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.
Chmielecki J; Peifer M; Jia P; Socci ND; Hutchinson K; Viale A; Zhao Z; Thomas RK; Pao W
Nucleic Acids Res; 2010 Nov; 38(20):6985-96. PubMed ID: 20587502
[TBL] [Abstract][Full Text] [Related]
13. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
14. Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
Fioretos T; Panagopoulos I; Lassen C; Swedin A; Billström R; Isaksson M; Strömbeck B; Olofsson T; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2001 Dec; 32(4):302-10. PubMed ID: 11746971
[TBL] [Abstract][Full Text] [Related]
15. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
[TBL] [Abstract][Full Text] [Related]
16. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
[TBL] [Abstract][Full Text] [Related]
17. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
[No Abstract] [Full Text] [Related]
18. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder.
Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC
Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377
[TBL] [Abstract][Full Text] [Related]
19. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.
Erben P; Gosenca D; Müller MC; Reinhard J; Score J; Del Valle F; Walz C; Mix J; Metzgeroth G; Ernst T; Haferlach C; Cross NC; Hochhaus A; Reiter A
Haematologica; 2010 May; 95(5):738-44. PubMed ID: 20107158
[TBL] [Abstract][Full Text] [Related]
20. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A
Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
